Picture of NeuroPace logo

NPCE — NeuroPace News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Neuropace Inc expected to post a loss of 24 cents a share - Earnings Preview

Neuropace Inc NPCE.OQ NPCE.O is expected to show a rise in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

The Mountain View California-based  company is expected to report a 20.5% increase in revenue to $21.847 million from $18.12 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Neuropace Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Neuropace Inc is $17.00​, above​ its last closing price of $12.89. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
Dec. 31 2024-0.22-0.22-0.18Beat19.2
Sep. 30 2024-0.27-0.27-0.19Beat29.2
Jun. 30 2024-0.30-0.30-0.26Beat13.3​
Mar. 31 2024-0.32-0.32-0.32Met0.5
​​Dec. 31 2023-0.30-0.31-0.23Beat27
Sep. 30 2023-0.41-0.41-0.28Beat31.7​
Jun. 30 2023-0.46-0.46-0.36Beat22.6
Mar. 31 2023-0.46-0.46-0.41Beat10.1
This summary was machine generated May 10 at 00:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on NeuroPace

See all news